ライフサイエンスコーパス: haematological

1 7%]), pain (122/472 [26%] vs 135/468 [29%]), haematological (124/472 [26%] vs 73/468 [16%]), and gast

2 ith most of the grade 3 adverse events being haematological (45%).

3 Pegylated interferon alfa-2a induced haematological (66 [80%] of 83 patients) and molecular r

4 The most common toxicities were haematological (77 [84%] for tacrolimus, mycophenolate m

5 Haematological abnormalities were common, including rais

6 erse events (irrespective of causality) were haematological abnormalities-namely, anaemia (in nine [9

7 peak) would be revealed when controlling for haematological adaptations.

8 patients after ten of 20 cancers, including haematological (adjusted HR 1.94, 1.66-2.25, with non-Ho

9 control group), whereas the most common non-haematological adverse event was hypokalaemia (25 [17%]

10 mab group than in the placebo group included haematological adverse events (neutropenia in 44 [54%] o

11 INTERPRETATION: Despite an increase in haematological adverse events and second primary maligna

12 d grade 3-4 pain, and 12 (15%) had grade 3-4 haematological adverse events during chemoradiation.

13 The most common non-haematological adverse events included electrolyte distu

14 most common grade 3-4 treatment-related non-haematological adverse events included fatigue (34 [6%]

15 Grade 3-4 haematological adverse events occurred in 32 (14%) of 23

16 Grade 3-4 non-haematological adverse events occurring in more than one

17 The most frequent haematological adverse events of any grade were anaemia

18 The most common grade 3-4 haematological adverse events reported, irrespective of

19 Overall, the only grade 3 or 4 non-haematological adverse events that occurred in at least

20 Non-haematological adverse events were generally lower with

21 olerated dose, the most common grade 3-4 non-haematological adverse events were hyperglycaemia (ten [

22 Frequent grade 3-4 non-haematological adverse events were hypertension (five [7

23 Grade 3-4 haematological adverse events were more common in the tu

24 The most common grade 3-4 haematological adverse events were neutropenia (five [28

25 No grade 4 non-haematological adverse events were reported.

26 Frequencies of non-haematological adverse events were similar in the R-CHOP

27 The main grade 3/4 toxicities were haematological: anaemia (45%), thrombocytopenia (45%), a

28 Haematological analysis was performed using a Sysmex XN-

29 18 (8%) haematological and 14 (6%) solid tumour second primary m

30 GLOBE LV-mediated IUGT normalised the haematological and anatomical phenotype in a heterozygou

31 t in the gene SH2B3, is also associated with haematological and autoimmune disorders, suggesting that

32 ease is associated with a high prevalence of haematological and biochemical abnormalities, even in mi

33 tting, and few data exist for the associated haematological and biochemical abnormalities.

34 g reverse-transcriptase-PCR (RT-PCR) and for haematological and biochemical analysis.

35 atures on admission, including observations, haematological and biochemical characteristics, were use

36 COG) performance status of 0-1, and adequate haematological and biochemical parameters.

37 amount of parasite genome, and assessed for haematological and biochemical parameters.

38 rogression or intolerance), and had adequate haematological and biochemical parameters.

39 d Tumors version 1.1 (RECIST v1.1), adequate haematological and end-organ function, and no autoimmune

40 mors version 1.1 (RECIST v1.1), and adequate haematological and end-organ function.

41 Three haematological and five solid tumour second primary mali

42 Given that similar haematological and gastrointestinal defects were observe

43 lignant disorders and other life-threatening haematological and genetic diseases.

44 oss of Nrbp1 results in tumourigenesis, with haematological and intestinal tumours predominating, and

45 ylated interferon alfa-2a can induce durable haematological and molecular responses in patients with

46 lenalidomide group, compared with three (1%) haematological and nine (4%) solid tumour second primary

47 Oral eliglustat maintained haematological and organ volume stability in adults with

48 an uncertain risk of tissue contamination in haematological and other malignancies.

49 y Group performance status 0-2, and adequate haematological and renal function.

50 ients assigned temozolomide, and were mainly haematological and reversible.

51 Both haematological and solid cancers initially gain chromoso

52 in a large number of malignancies, including haematological and solid cancers.

53 nesis, progression, and prognosis of various haematological and solid tumours.

54 sorder in adults with cancer in oncological, haematological, and palliative-care settings.

55 with cancer, including those in oncological, haematological, and palliative-care settings.

56 he sensory and autonomic nervous system, and haematological anomalies.

57 The most common adverse events were haematological, behavioural (eg, fatigue), musculoskelet

58 toxicity in zebrafish embryos, do not cause haematological, biochemical or histological abnormalitie

59 Patients who died from haematological cancer (PRs 0.46-0.52), who were single,

60 ith a variety of adverse outcomes, including haematological cancer and death.

61 overlap with human primary immunodeficiency, haematological cancer somatic mutations and knockout mou

62 tions has recently been associated with both haematological cancer(2-4) and coronary heart disease(5)

63 ent, along with known at risk groups such as haematological cancer, lung cancer, older age, and depri

64 RCH is associated with an increased risk for haematological cancers [2].

65 these data suggest a potential for treating haematological cancers harbouring U2AF1 mutations with p

66 logical malignancy, representing over 10% of haematological cancers in the USA.

67 CXCR4) is attractive for targeted therapy of haematological cancers, given its expression in multiple

68 onjugates (ADCs) are promising therapies for haematological cancers.

69 ter hypoxia on brain cell death and systemic haematological changes compared to LPS and hypoxia alone

70 on skin and bone tissues besides than on the haematological compartment.

71 ficiency, liver involvement, neurological or haematological complications, uteroplacental dysfunction

72 if they assessed only individuals with known haematological conditions, were family studies, or had i

73 lobulin and does not meet previously defined haematological criteria for treatment of a specific mali

74 Although Ppara(-/-) mice show no haematological difference from wild-type mice in both no

75 edge of how bone marrow niches contribute to haematological disease predisposition, initiation, progr

76 f IMN and one died from complications of the haematological disease.

77 on (JAK-STAT) signalling pathway in cancers, haematological diseases, and chronic inflammatory condit

78 providing meaningful clinical insights into haematological diseases, and these could not be revealed

79 ARCH also confers an increased risk for non-haematological diseases, such as cardiovascular disease,

80 d M7 were stratified by antecedent malignant haematological disorder (yes or no) and age (18-60 years

81 ignalling, defining an atypical form of this haematological disorder rapidly progressing to acute mye

82 ell disease is a common and life-threatening haematological disorder that affects millions of people

83 to treat over 200 patients with 10 different haematological disorders (including primary immunodefici

84 ing CCAM, we have analysed transcriptomes of haematological disorders and those of normal haematopoie

85 Furthermore, when patients with haematological disorders do enrol into hospice care, the

86 ular disorders, and liver disease in Europe; haematological disorders in North America; and respirato

87 ition and wasting, parasitic infections, and haematological disorders in the Africa region; respirato

88 fic cellular approaches for the treatment of haematological disorders requiring myelosuppressive regi

89 ssion, followed by malnutrition and wasting, haematological disorders, and, in the African region, ma

90 atopoietic stem cells could aid treatment of haematological disorders.

91 susceptibility to LOY is associated with non-haematological effects on health in both men and women,

92 Haematological exploration found an indolent IgG-kappa m

93 RECENT FINDINGS: This review explores the haematological features of Gaucher disease in the contex

94 This 16-year-old male had neurological and haematological features that emulate those of Ireb2 knoc

95 on of neurological, endocrine, exocrine, and haematological findings that is caused by biallelic MADD

96 ife expectancy of 6 months or more; adequate haematological function for 28 days or more; and one or

97 The most common non-haematological grade 3 adverse events were fever (nine [

98 The most common non-haematological grade 3 or 4 adverse events were infectio

99 who received CRT plus cetuximab had more non-haematological grade 3 or 4 toxicities (102 [79%] of 129

100 openia after engraftment was the most common haematological grade 3-4 adverse event (nine) but was tr

101 The most common non-haematological grade 3-5 treatment-emergent adverse even

102 ansplantations, and address the issue by the haematological group-myeloid and lymphoid-of diseases, w

103 Solid Tumors (RECIST) version 1.1, adequate haematological, hepatic, and renal function, and immune-

104 ) performance status of 0 or 1, and adequate haematological, hepatic, and renal function.

105 utes to human diseases, including cancer and haematological, immunological and neurological diseases.

106 progression-free survival, overall survival, haematological improvement measured by haemoglobin, time

107 Sustained haematological improvement was noted in 72 (79%) of 91 p

108 ial remission, marrow complete remission, or haematological improvement were included in the response

109 tial response, marrow complete response, and haematological improvement) assessed in all patients who

110 n-free survival, overall survival, sustained haematological improvement, and immunological improvemen

111 modified International Working Group-defined haematological improvement-erythroid (HI-E), defined as

112 or worse adverse events in both groups were haematological, including anaemia (150 [48%] of 313 pati

113 adverse events for patients taking CVD were haematological, including neutropenia (18 [7%] patients)

114 events for patients taking lenalidomide were haematological, including neutropenia (362 [33%] patient

115 The most common all-grade toxic effects were haematological, including thrombocytopenia in 63 (74%) p

116 tolerability, including adverse events, non-haematological laboratory grade 3-4 toxic effects, and c

117 -C-001 trial enrolled patients with advanced haematological malignancies (2008 WHO criteria) harbouri

118 Patients with haematological malignancies (leukaemia, lymphoma, and my

119 For people with haematological malignancies (n=224), the most troublesom

120 de, we randomly assigned (1:1) patients with haematological malignancies aged 18 years and older to r

121 age-specific tumour types, including several haematological malignancies and androgen receptor-positi

122 ges, TAMs, are an abundant part of solid and haematological malignancies and have been linked with pr

123 have demonstrated the involvement of GFI1 in haematological malignancies and have suggested that low

124 s of CAR-T therapy for the treatment of both haematological malignancies and HIV.

125 ic event linked to increased risk of primary haematological malignancies and increased all-cause mort

126 rent gene fusions, typically associated with haematological malignancies and rare bone and soft-tissu

127 s with multiple myeloma, but also with other haematological malignancies and solid tumours.

128 opic effects of the BAK1 variant on multiple haematological malignancies and specific effects of IGF2

129 essential for the treatment of patients with haematological malignancies and the recipients of stem-c

130 Patients with haematological malignancies are at high risk of infectio

131 Patients with haematological malignancies are less likely to use palli

132 Tet2 mutations are drivers in haematological malignancies but Tet1 had an oncogenic ro

133 myeloproliferative neoplasms are a group of haematological malignancies characterised by pathologica

134 d physical decline over time for people with haematological malignancies compared with people with so

135 tries, high-quality epidemiological data for haematological malignancies from these regions are scarc

136 lear benefits of hospice care, patients with haematological malignancies have the lowest rates of enr

137 ated with substantial familial clustering of haematological malignancies indicated that this gene is

138 The immunocompromised adult population with haematological malignancies is at high risk for herpes z

139 Specific haematological malignancies occur in different contexts

140 mmunogenicity of this vaccine in adults with haematological malignancies receiving immunosuppressive

141 Community patients with haematological malignancies receiving palliative care ha

142 in the preparative regimens of patients with haematological malignancies selected for unrelated donor

143 ncer-directed therapy in adult patients with haematological malignancies that reported on PRO measure

144 igible patients were diagnosed with advanced haematological malignancies treatable by allogeneic HSCT

145 y is increasingly relevant for patients with haematological malignancies treated with chronically adm

146 Haematological malignancies were defined by morphology c

147 s of the respiratory system or heart, or for haematological malignancies were found.

148 Haematological malignancies were previously thought to b

149 Adult patients with non-leukaemia haematological malignancies who had disease progression

150 er correction for age and sex, patients with haematological malignancies who had recent chemotherapy

151 utcomes for adult patients (>=18 years) with haematological malignancies who underwent their first al

152 gical roles of miRNAs in the pathogenesis of haematological malignancies will allow rational stratifi

153 approach for people living with HIV who have haematological malignancies with poor prognosis.

154 in decreasing mortality from HIV-associated haematological malignancies worldwide.

155 with diseases such as solid-tumour cancers, haematological malignancies, and chronic digestive disea

156 tatus (patients with HIV, immunosuppression, haematological malignancies, and previous organ transpla

157 f the most effective immunotherapies against haematological malignancies, but significant clinical su

158 cell transplantation-associated toxicity in haematological malignancies, contributing to mortality.

159 treatment of multiple sclerosis, psoriasis, haematological malignancies, Crohn's disease, and rheuma

160 ancies receiving chemotherapy and those with haematological malignancies, either receiving or not rec

161 to the development of familial and sporadic haematological malignancies, including acute lymphoblast

162 py has shown remarkable clinical efficacy in haematological malignancies, its success in combating so

163 e reported single-agent activity in advanced haematological malignancies, mechanisms determining the

164 e first successful therapy for patients with haematological malignancies, predominantly owing to graf

165 ncer cell lines and primary samples of human haematological malignancies, reveal that senescence-asso

166 Of the haematological malignancies, T-cell lymphomas have an ex

167 For haematological malignancies, targeted therapies, such as

168 tations frequently occur in various types of haematological malignancies, the mechanism by which they

169 optimise end-of-life care for patients with haematological malignancies.

170 atients receiving other types of therapy for haematological malignancies.

171 nagement of cytomegalovirus in patients with haematological malignancies.

172 or herpes zoster prevention in patients with haematological malignancies.

173 become the mainstay for treatment of certain haematological malignancies.

174 emopoiesis have increased risk of developing haematological malignancies.

175 atients were aged 18-55 years, had high-risk haematological malignancies.

176 ich are recurrently deleted/mutated in human haematological malignancies.

177 lls represent a potent new approach to treat haematological malignancies.

178 are members of common oncogenic pathways in haematological malignancies.

179 (median age 45.8 years [IQR 33.2-55.5]) with haematological malignancies.

180 tion when reporting PROs in future trials of haematological malignancies.

181 recommended dose of OTX015 in patients with haematological malignancies.

182 ty was noted in 23 (49%) of 47 patients with haematological malignancies.

183 palliative care service use by patients with haematological malignancies.

184 rolled trials (RCTs) involving patients with haematological malignancies.

185 y tested in individuals with other solid and haematological malignancies.

186 mortality records to ascertain occurrence of haematological malignancies.

187 actic platelet transfusions in patients with haematological malignancies.

188 ns or point mutations is a frequent event in haematological malignancies.

189 donor transplantation in adult patients with haematological malignancies.

190 role in the development of various solid and haematological malignancies.

191 on and progression of a variety of solid and haematological malignancies.

192 ls have changed the therapeutic landscape in haematological malignancies.

193 estigations for a range of solid tumours and haematological malignancies.

194 ally administered therapies in patients with haematological malignancies.

195 e in the pathogenesis and chemoresistance of haematological malignancies.

196 -related cancer has emerged, including other haematological malignancies.

197 solid tumours and 18 (28%) were approved for haematological malignancies.

198 ted pathways that are shared across multiple haematological malignancies.

199 r solid tumours, and 0.149 (0.090-0.247) for haematological malignancies.

200 prevention in patients with solid tumour or haematological malignancies.

201 n 3 days of death than are patients with non-haematological malignancies.

202 nto the clinical management of patients with haematological malignancies.

203 lso observed for multiple cancers, including haematological malignancies.

204 model that mimics the mutations observed in haematological malignancies.

205 aving treatment for individuals with HIV and haematological malignancies; challenges include identify

206 ndrome is a complication of chemotherapy for haematological malignancies; in particular, aggressive l

207 Eligible patients had a haematological malignancy (leukaemia, myelodysplastic sy

208 e patients were aged 16 to 70 years with any haematological malignancy and a Karnofsky score of at le

209 ultiple myeloma is the second most prevalent haematological malignancy and is incurable.

210 The haematological malignancy arm was terminated early becau

211 OTX015 inhibits proliferation in many haematological malignancy cell lines and patient cells,

212 nterim analysis; therefore, all prespecified haematological malignancy endpoints were deemed explorat

213 In the haematological malignancy group, VZV vaccine was well to

214 ting a novel TET2 loss-mediated mechanism of haematological malignancy pathogenesis.

215 eriod, the risk of developing any SPM or any haematological malignancy was significantly reduced in p

216 l acute lymphoblastic leukaemia (T-ALL) is a haematological malignancy with a dismal overall prognosi

217 s machine learning's current applications in haematological malignancy, and summarises important conc

218 These applications include the management of haematological malignancy, in which machine learning has

219 Multiple myeloma is an incurable haematological malignancy, representing over 10% of haem

220 ency with age and predisposes individuals to haematological malignancy.

221 d first-line treatment in patients with this haematological malignancy.

222 ted adults (aged >/=18 years) with high-risk haematological malignant diseases who were candidates fo

223 an intensive therapy used to treat high-risk haematological malignant disorders and other life-threat

224 y mass, body temperature, or biochemical and haematological markers of toxicity.

225 Skin moisture, age, haematological measures, nutrition and general health st

226 ety assessments included renal, hepatic, and haematological monitoring and recording of adverse event

227 le the application of PGD to the less common haematological mutations, and the diagnosis of nonaffect

228 FL represents ~5% of all haematological neoplasms and ~20-25% of all new non-Hodg

229 are often associated with increased risk of haematological or neurological toxicity.

230 s analysis, including standard chemistry and haematological panels, were taken on each treatment day.

231 Secondary endpoints included haematological parameters and a safety analysis of adver

232 aluate the effect of thermal injury on novel haematological parameters and to study their association

233 modified Rankin Scale (mRS), Barthel Index, haematological parameters, serious adverse events and de

234 progenitor proliferation contributes to the haematological phenotype of SDS.

235 OTX015 is active in haematological preclinical entities including leukaemia,

236 e populations self-maintain independently of haematological progenitors prompted us to consider organ

237 lowing 6 weeks of ET is mainly determined by haematological rather than skeletal muscle adaptations.

238 CRp), and complete remission with incomplete haematological recovery (CRi) achieved at any time and a

239 esponse or complete response with incomplete haematological recovery 28 days after infusion.

240 s complete remission (CR) or CR with partial haematological recovery of peripheral blood counts (CRh)

241 46 (18%) complete remission with incomplete haematological recovery, and 25 (10%) partial remission

242 d complete response with or without complete haematological recovery, and two (10%) showed partial re

243 ission or complete remission with incomplete haematological recovery.

244 kaemia had high risk of remission failure or haematological relapse (72% [95% CI 40-100] at 10 years

245 d leukaemia in first or consecutive complete haematological remission (blast counts <5% in bone marro

246 The probability of maintaining complete haematological remission was 55% (95% CI 32-73) and the

247 lity of primary composite response, complete haematological remission, overall clinicohaematological

248 progressive metastatic disease, and adequate haematological, renal, and hepatic function.

249 xpectancy of at least 6 months, and adequate haematological, renal, and liver function.

250 FISH analysis of TOP2A status; and adequate haematological, renal, hepatic, and cardiac function.

251 26 (39%) of 66 haematological responders and 25 (71%) of 35 molecular r

252 The primary endpoint was haematological response at 3 months after infusion.

253 14 patients (56%; 95% CI 35-76) had a haematological response at 3 months.

254 elapsed and refractory disease suggests that haematological response can be achieved without continue

255 Complete haematological response was defined as normalisation of

256 study was the proportion of patients with a haematological response.

257 dies contribute to a deeper understanding of haematological responses in patients with chronic infect

258 Haematological responses were assessed every 3-6 months

259 (HR 1.1 [95% CI 0.62-2.00]; p=0.72), and of haematological second primary malignancies were 3.1% (95

260 cies, solid second primary malignancies, and haematological second primary malignancies, and were ana

261 lidomide had an increased risk of developing haematological second primary malignancies, driven mainl

262 [95% CI 0.33-2.24]; p=0.76) did not increase haematological second primary malignancy risk versus mel

263 plus oral melphalan significantly increased haematological second primary malignancy risk versus mel

264 Grade 3 or 4 non-haematological serious adverse events included grade 3 a

265 no significant differences were seen in any haematological, serum chemistry, or radiological assessm

266 duals across 14 countries in oncological and haematological settings.

267 inst a broad range of cancers, including non-haematological solid tumours.

268 olerance, oxygen uptake rates, acid-base and haematological status) were conducted upon 14-17 days of

269 verse events were fatigue (six patients) and haematological (ten patients).

270 nd by electrocardiography, echocardiography, haematological testing, urinalysis, and blood chemistry.

271 Haematological tests (blood sugar, HbA1c and lipid profi

272 he most common grade 3-4 adverse events were haematological; the most common of these was grade 4 neu

273 intermittent treatment had grade 3 or worse haematological toxic effects (72 [15%] vs 60 [12%]), whe

274 than in the capecitabine group had grade 3-4 haematological toxic effects (seven [18%] vs none, p=0.0

275 fects (seven [18%] vs none, p=0.008) and non-haematological toxic effects (ten [26%] vs four [12%], p

276 yelofibrosis who had suboptimal responses or haematological toxic effects with ruxolitinib.

277 the phase 2 portion of the study, grade 3-4 haematological toxicities included neutropenia (29 patie

278 Grade 3/4 haematological toxicities were rare.With Gem/Carb regime

279 t [28%]), infections (30 [54%] vs 19 [66%]), haematological toxicity (28 [50%] vs five [17%]), and ge

280 [11%]), infection (42 [19%] vs 22 [10%]) and haematological toxicity (48 [22%] vs 27 [12%]) were repo

281 2.04, 1.49-2.78, p<0.0001, respectively) and haematological toxicity (adjusted RR 9.76, 95% CI 3.03-3

282 a (13 [5%] vs none) but reduced incidence of haematological toxicity (grade >/= 3 neutropenia 35 [13%

283 One (1%) patient had a grade 4 non-haematological toxicity (neurotoxicity).

284 r, RB-CHOP was not associated with increased haematological toxicity and 398 [87.1%] of 459 participa

285 cer therapies, such as chemoradiation, cause haematological toxicity primarily by activating the tumo

286 as associated with more frequent grade 4 non-haematological toxicity than MAP (35 [12%] of 301 in the

287 ive patients had grade 3 or grade 4) and non-haematological toxicity was fatigue (28 [37%] patients;

288 atients) and neutropenia (26 [58%]), and non-haematological toxicity was infrequent.

289 ological toxicity was uncommon; as expected, haematological toxicity was more common in patients trea

290 Grade 4 haematological toxicity was more frequent in patients tr

291 Grade 4 non-haematological toxicity was uncommon; as expected, haema

292 apeutic in rats and dogs resulted in minimal haematological toxicity, as well as the absence of neutr

293 st common grade 3 or worse adverse event was haematological toxicity, reported in 178 (39.8%) of 447

294 causal relationships between a wide range of haematological traits and ischaemic stroke and its subty

295 However, whether haematological traits contribute equally to all ischaemi

296 published genome-wide association studies of haematological traits involving over 375 000 individuals

297 reek population to 4.6% in the isolate) with haematological traits, for example, with mean corpuscula

298 e clotting cascade, as well as several other haematological traits, in the pathogenesis of CES and po

299 is factor-alpha inhibitors, who had an organ/haematological transplant, or with silicosis.

300 rare cancers, with the largest increases for haematological tumours and sarcomas.

301 cy endpoint was percentage of patients whose haematological variables and organ volumes remained stab